TCTAP A-119 Incidence and Procedural Outcome of Bicuspid Aortic Valve in 684 Patients Undergoing Transcatheter Aortic Valve Implantation  by Kim, Won-Keun et al.
S60 J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 5 , N O . 1 7 , S U P P L S , 2 0 1 5VALVULAR HEART DISEASE
(TCTAP A-116 TO TCTAP A-123)
TCTAP A-116
Comparison of Aortic Annulus Dimensions by Multidetecter Computed
Tomography Between Japanese and European Patients Undergoing
Transcatheter Aortic Valve Implantation. Results from the Japanese
Multicenter Registry and European Single Center Cohort
Yusuke Watanabe,1 Hideyuki Kawashima,1 Ken Kozuma,1
Bernard Chevalier,2 Thierry Lefevre,3 Marie-Claude Morice,3
Masanori Yamamoto,4 Kentaro Hayashida5
1Teikyo University Hospital, Japan; 2Institut Cardio-Vasculaire Paris-
Sud, France; 3Institut Hospitalier Jacques Cartier, France; 4Toyohashi
Heart Center, Japan; 5Keio University School of Medicine, Japan
BACKGROUND The purpose of this study was to compare directly the
aortic annulus measurement by multi detector computed tomography
(MDCT) between a Japanese multi-center registry and a European
single-center experience undergoing transcatheter aortic valve im-
plantation (TAVI).
METHODS Between October 2013 and July 2014, 90 patients who are
undergoing TAVI were prospectively included in the OCEAN-TAVI
registry from 3 Japanese centers (Keio university hospital, Toyohashi
heart center, and Teikyo university hospital). Between March 20 09
and December 201 2, 181 consecutive patients undergoing TAVI who
had pre-procedural MDCT at Institut Cardiovasculaire Paris Sud were
prospectively included in the European cohort. We compared MDCT
aortic annulus measurement of these 2 cohorts.
RESULTS Patients were of similar age (85.0 [Interquartile Range (IQR)
82.5-87.5] vs 84.0
[IQR 80.5-87.5] years, p¼0.83), and body surface area was smaller in
the Japanese registry (1.400.15 vs 1.760.00319, p<0.01). All annulus
dimensions including short annulus diameter (19.42.0 vs 22.62.3,
p<0.01), large annulus diameter (24.71.9 vs 27.62.5, p<0.01),
calculated average annulus diameter by area (CAAD, 22.41.6 vs
25.62.2, p<0.01), left coronary ostium height (13.6 [IQR 12.0-15.0]
vs15.1 [IQR 13.5-17.2] , p<0.01) and right coronary ostium height (15.9
[IQR 14.5-17.5] vs 17.7 [IQR 16.0-19.7] , p<0.01) were smaller in a
Japanese registry. With hypothetical prosthesis sizing based on CAAD
(20mm Edwards Sapien XT for <20 mm; 23mm: 20 to 22mm; 26mm: 22
to 25 mm; 29mm: >25 mm), the use of 20mm, 23mm, 26mm, and
29mm Edwards valve compared with a Japanese registry and an Eu-
ropean cohort were 2.2% vs 0%, 51.1% vs 12.7%, 44.4% vs 43.1%, and
2.2% vs 44.2% (p<0.01), respectively.
CONCLUSION Japanese patients had smaller annulus dimensions by
MDCT compared with European patients. Prosthesis sizing by CAAD
showed smaller size of prosthesis would be required among Asian
patients undergoing TAVI.
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BACKGROUND MitraClip has been increasingly performed in Asian
countries since 2011. Our study is to evaluate the effectiveness of
improvement of heart failure symptoms and functional status in heart
failure patients with percutaneous method of reduction of mitral
incompetence (MI) with the MitraClip system.
METHODS Patients were selected for the MitraClip procedure based
on the consensus of the Heart Team in our center. Between February
2012 and December 2013, 24 patients considered high risk as surgical
candidates undergone percutaneous therapy for severe MI using the
MitraClip. All the patients underwent clinical and echocardiographic
evaluation at baseline, and at 6-month follow-up. Mortality data,
including cause of death, were collected.
RESULTS The mean age was 67 years (53–86), 58.3% (n ¼ 14) was male
with a mean logistic EuroSCORE of 21%. At baseline, 90% of patients
were in New York Heart Association (NYHA) functional class III or IV
and 46% of patients had a left ventricular ejection fraction
(LVEF) 50%. 45.8% (n¼11) patients presented with functional mitral
regurgitation (FMR) and 54.2% (n¼13) patients presented with
degenerative mitral regurgitation (DMR). Procedural success was
achieved in 96% of patients. Severity of MR was reduced in allsuccessfully treated patients, 18 (75%) were discharged with MR 2þ.
There was improvement in the severity of MI at 6 months, compared
with baseline (p < 0.0001), Thirty-day mortality was 6%. At 6 months,
approximately 90% of patients had New York Heart Association
functional class II or class I (p <0.0001).
CONCLUSION Results of the study demonstrate that mitral incom-
petence reduction with MitraClip treatment is effective, low risk, and
leads to signiﬁcant improvement in NYHA functional class in
approximately 90% of patients with heart failure.TCTAP A-118
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BACKGROUND A novel and innovative transfemoral aortic valve im-
plantation (TF-AVI) system was used to treat 89 patients with severe
aortic stenosis in a CE mark trial. This single-arm registry was per-
formed at 6 clinical sites in Brazil, Germany and Japan. The ﬁrst pa-
tient was implanted in January 2012 and the last study implant
procedure took place in early October 2013.
METHODS These 89 high-risk patients afﬂicted with severe aortic
stenosis were treated in single-arm trials conducted at 6 centers
in Brazil, Germany and Japan. Treated patients have a mean age of
83.7  4.4 years, an STS Score of 7.5  8.2%, and a logistic
EuroSCORE of 26.6 7.7%. Baseline mean aortic gradient was 43.6
 17.1 mmHg and mean AVA was 0.7  0.2 cm2. Nearly all patients
presented in NYHA ClassIII/IV at screening (n¼84) and 65.2% were
female. All patients provided EC-approved written informed
consent.
RESULTS Procedure success rate was 94.4% (n¼84) with 3 valve-in-
valve procedures and 2 failed implantations due to one instance of
annular rupture and one case of bioprosthesis leaﬂet tear. Both failed
procedures occurred during post-dilatation. The implant procedures
were performed using small, medium and large valves covering an
annular range of 21 mm to 27 mm. At 30 days there were 3 deaths, 2
strokes and no MI reported. Only 8 new pacemaker implantations
were required for a rate of 9.0%. Freedom from VARC II combined
safety at 30 days was 84.3% (n¼75). Echocardiography at 30 days
revealed only 4 patients (4.9%) with moderate (grade 2) paravalvular
leak – there were no patients with a paravalvular leak above grade 2.
The mean gradient was reduced to 8.0  2.9 mmHg and the aortic
valve area was 1.8 0.3 cm2. At 12 months, all-cause mortality was
22.5% (n¼20) with 3 additional strokes and one myocardial infarction
reported.
CONCLUSION Outcomes from treatment with this new 2ndGeneration
TF-AVI system conﬁrm its feasibility of use and safety out to one year.
In September 2014 this device received CE mark approval, and further
postmarket data may be expected in the near future.
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BACKGROUND Data on transcatheter aortic valve implantation
(TAVI)in bicuspid aortic valve (BAV) is rare and inconsistent,
particularly concerning incidence and outcome. In part this might be
attributed to an inadequate recognition of this condition and/or a
relatively low sensitivity of echocardiography. However, multislice
computed tomography (MSCT) is thought to have a better diagnostic
accuracy.
The aim of this retrospective analysis was to review MSCTs for
detection and classiﬁcation of BAVs and verify the impact on proce-
dural outcome.
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aortic stenosis who underwent TAVI in our institution between 2012
and 2014 with available pre-procedural MSCT were included. For
adjudication of the leaﬂet phenotype, diastolic (70%) and systolic
(30%) reconstructions were used. Genuine BAV was diagnosed ac-
cording to Sievers et al. (type 0: purely bileaﬂet; type 1: triﬂeaﬂet
anlage, 1 raphe; type 2: trileaftlet anlage, 2 raphes). Functional BAV
was deﬁned as tricuspid conﬁguration with symmetric geometry of all
three cusps and commissures in diastole – assuming a trileaftlet an-
lage – and bicuspid conﬁguration during systole unmasking a fusion of
two adjacent cusps. Device success according to VARC II criteria was
compared between BAV and non-BAV patients.
RESULTS Mean age was 82.2 5.9 years, logistic Euro score was 24.3 
12.2%, and 54.2% were female. With echocardiography only 15 (2.1%)
cases were classiﬁed as BAV, whereas MSCT revealed a congenital
BAV in 40 (5.8 %) cases (type 0, 1, and 2 in 7.5%, 77.5%, and 20%
respectively). A trileaﬂet anlage with functional bicuspid anatomy
was present in 13 (1.9%) patients. The overall incidence of functional
and genuine BAV was much higher than diagnosed with pre-proce-
dural echocardiography (p ¼ 0.001).
In patients with BAV, the combined endpoint of device success
according to VARC 2 was non-signiﬁcantly lower than in those with
tri-leaﬂet aortic valves (90.8% vs. 83.0%; p ¼ 0.07). However, the rate
of device-related procedural complications including device malpo-
sitioning, embolization and/or valve-in-valve implantation, was
signiﬁcantly higher in the BAV-group (11.3% vs. 3.2%; p ¼ 0.01).
CONCLUSION MSCT facilitates the identiﬁcation and classiﬁcation of
genuine or functional BAV in TAVI patients. Given a higher rate of
procedural failures, a more attentive appreciation of a bicuspid
phenotype should be encouraged.
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BACKGROUND Rheumatic Mitral valve stenosis still is an important
cause of mortality and morbidity in certain parts of the world. Mostly
the morbidity is manifested through pulmonary function limitations
causing shortness of breath and poor tolerance to physical demands.
These in turn is caused by chronic pulmonary circulatory changes
from accumulation of water, proteins and proteoglycans in pulmonary
interstitium. The degree of pulmonary involvement is directly man-
ifested by the changes of pulmonary function test (PFT) and repair of
mitral valve pathology shows signiﬁcant improvement in PFT pa-
rameters as well as in symptoms. Percutaneous Transvenous Mitral
Commissurotomy (PTMC) is an option to repair pure mitral stenosis
with relatively less risk and economic burden.
METHODS A prospective study involving 58 patients of mitral steno-
sis having New York Heart Association (NYHA) II-IV class symptoms
was done. Patients with favorable valve morphology (Wilkin’s
score<10) were selected for PTMC. Echocardiographic evaluation and
PFT were done before and 7 days after PTMC and compared using
paired student’s T test and correlation between variables were
established with Pearson’s correlation analysis.
RESULTS Two patients died from procedural complication. Others
showed signiﬁcant improvement in symptoms and hemodynamic
measurements after successful PTMC.
Before PTMC, 19 patients (33.9%) were in NYHA class III, 36 patients
(64.3%) were in class II. After PTMC, majorities (37 patients, 66.1%)
were switched over to NYHA class I and remaining 18 patients (32.1%)
were in class II. Pulmonary artery systolic pressure did not show any
correlation with forced vital capacity.Echocardiographic
ParameterGroupp valueBefore PTMC After PTMCMitral valve area
(square cm)0.764  0.1257 1.404  0.1194 <0.001Transmitral peak
pressure gradient
(mmHg)26.43  5.62 11.36  2.4000 <0.001Left atrial diameter
(mm)47.23  5.350 40.18  5.557 <0.001Pulmonary artery
systolic pressure
(mmHg)57.73  17.03 31.27 8.30 <0.001Pulmonary function
test ﬁndingsFEV1 (% of predicted
value)60.18  13.054 78.32  11.874 <0.001FVC (% of predicted
value)53.80  12.313 68.57  11.662 <0.001FEV1/FVC 112.64  16.292 114.98  12.714 0.33
PEF (L/min) 223.75  62.3215 372.05  62.200 <0.001CONCLUSION Patients with severe mitral stenosis have impaired
pulmonary function which is of restrictive type. Symptom often does
not correlate with the severity of the disease. Successful PTMC im-
proves pulmonary function, as well as, clinical status. PTMC should be
done in suitable cases to reduce morbidity in mitral stenosis. Also,
assessment of lung function in patients with mitral stenosis may aid
in timely decision-making before adopting the interventional strategy
of treatment.
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BACKGROUND Rheumatic fever and rheumatic heart disease
continue to be the major health problem in all developing countries
including Bangladesh. Percutaneous Transvenous mitral Commissur-
otomy (PTMC) is an established non-surgical modality for the treat-
ment of severe rheumatic mitral valve stenosis. The purpose of this
study was to evaluate our immediate and in-hospital results of
Percutaneous Transvenous Mitral Commissurotomy (PTMC) in pa-
tients with restenosis with previous mitral surgery (CMC).
METHODS The study group included 880 consecutive patients who
underwent PTMC at the National Institute of cardiovascular Diseases
(NICVD), Dhaka and Al –Helal Heart Institute, Mirpur, Euro-Bangla
Heart Hospital, Lalmatia, Dhaka between May 2003 and December
2012. Safety, efﬁcacy and in-hospital results of percutaneous trans-
venous mitral commissurotomy were analyzed in 800 patients un-
derwent PTMC without previous CMC (group 1) and compared with 60
those of with previous CMC (group 2).
RESULTS Baseline demographic and clinical characteristics were
similar in the 800 patients without previous CMC (group-1) and the 80
patients with previous CMC (group-2) during the procedure. In the
whole study group mitral valve area (MVA) was 0.85  0.09 cm2 prior
to PTMC, and increased to 1.76  0.07 cm2 after the procedure (p ¼
0.0001). The mean increase in MVA was 0.78  0.31 cm2 in the group-1
and 0.79  0.41 cm2 in the group-2 (NS). During the procedure or in-
hospital after PTMC, embolic events were recorded in 3 patients in
group-1 and 2 patients ingroup-2 (NS). The frequency of minor he-
matoma at puncture site in 15 patients in group-1 vs. 13 patients in
group-2 and the development of pericardial tamponade and urgent
pericardiocentesis in 3 patients ingroup-1 vs. 3 patients in group-2
were similar in both groups.
CONCLUSION PTMC in selected patients with mitral restenosis after
previous surgical commissurotomy (CMC) can be performed safely
and with similar immediate efﬁcacy and in-hospital outcome in pa-
tients with Mitral stenosis.
